Skip to main content

Advertisement

SpringerLink
Log in

Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection

  • Original Article
  • Published:
Tumor Biology

Abstract

Mitotic arrest deficient-like 1 (MAD1L1) whose dysfunction is associated with chromosomal instability plays a pathogenic role in a few human cancers. However, the status of MAD1L1 expression in small-cell lung cancer (SCLC) remains unknown. Immunohistochemistry was used to determine the expression of MAD1L1 protein in 32 lymph node metastasis (LN-M) tissues and 88 primary SCLCs compared with 32 adjacent noncancerous tissues. The associations of MAD1L1 protein expression with the clinicopathologic features and clinical outcomes in patients with SCLC were analyzed. The ratio of MAD1L1 positive expression was higher in primary SCLC tissues (39.8 %) and LN-M tissues (46.9 %) compared with adjacent noncancerous tissues (9.4 %). MAD1L1 positive expression was associated with tumor-node-metastasis (TNM) stage (P = 0.003), International Association for the Study of Lung Cancer (IASLC) stage (P = 0.004), tumor size (P = 0.015), lymph node metastasis (P = 0.014), and recurrence (P < 0.001). Multivariate analysis suggested that MAD1L1 positive expression was an independent factor for overall survival (hazard ratio (HR) 2.002; 95 % confidence interval (CI) 1.065–3.763; P = 0.031) and recurrence-free survival (HR 2.263; 95 % CI 1.197–4.276; P = 0.012). To sum up, MAD1L1 positive expression may be associated with tumour progression and metastasis in SCLCs and may thus serve as a new biomarker for prognosis in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  2. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294–9.

    Article  CAS  PubMed  Google Scholar 

  3. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.

    Article  PubMed  Google Scholar 

  4. Tartarone A, Lerose R, Ardito R, Troiani L, Tedesco B, Bozza G, et al. Long-term survival in small cell lung cancer: a case report and review of the literature. Future Oncol. 2014;10:523–8.

    Article  CAS  PubMed  Google Scholar 

  5. Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol. 2014;41:133–42.

    Article  CAS  PubMed  Google Scholar 

  6. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355–67.

    Article  CAS  PubMed  Google Scholar 

  7. Ma M, Wang M, Xu Y, Hu K, Liu H, Li L, et al. First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute. Zhongguo Fei Ai Za Zhi. 2014;17:8–14.

    PubMed  Google Scholar 

  8. Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463:184–90.

    Article  CAS  PubMed  Google Scholar 

  9. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007;67:1176–83.

    Article  CAS  PubMed  Google Scholar 

  10. Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A. 2010;107:13040–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell. 1998;93:81–91.

    Article  CAS  PubMed  Google Scholar 

  12. Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, et al. Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene. 2001;20:3301–5.

    Article  CAS  PubMed  Google Scholar 

  13. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 2006;12:405–10.

    Article  CAS  PubMed  Google Scholar 

  14. Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD, et al. Clinical implication of altered expression of Mad1 protein in human breast carcinoma. Cancer. 2000;88:1623–32.

    Article  CAS  PubMed  Google Scholar 

  15. Nomoto S, Haruki N, Takahashi T, Masuda A, Koshikawa T, Takahashi T, et al. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene. 1999;18:7180–3.

    Article  CAS  PubMed  Google Scholar 

  16. Guo Y, Zhang X, Yang M, Miao X, Shi Y, Yao J, et al. Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer. J Med Genet. 2010;47:616–22.

    Article  CAS  PubMed  Google Scholar 

  17. Coe BP, Lee EH, Chi B, Girard L, Minna JD, Gazdar AF, et al. Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines. Genes Chromosom Cancer. 2006;45:11–9.

    Article  CAS  PubMed  Google Scholar 

  18. Sun Q, Zhang X, Liu T, Liu X, Geng J, He X, et al. Increased expression of mitotic arrest deficient-like 1 (MAD1L1) is associated with poor prognosis and insensitive to taxol treatment in breast cancer. Breast Cancer Res Treat. 2013;140:323–30.

    Article  CAS  PubMed  Google Scholar 

  19. Kienitz A, Vogel C, Morales I, Müller R, Bastians H. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene. 2005;24:4301–10.

    Article  CAS  PubMed  Google Scholar 

  20. Tsukasaki K, Imaizumi Y, Tawara M, Fujimoto T, Fukushima T, Hata T, et al. Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV-1 genotype. Br J Haematol. 1999;105:369–75.

    Article  CAS  PubMed  Google Scholar 

  21. Chun AC, Jin DY. Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. J Biol Chem. 2003;278:37439–50.

    Article  CAS  PubMed  Google Scholar 

  22. Iwanaga Y, Jeang KT. Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant. Cancer Res. 2002;62:2618–24.

    CAS  PubMed  Google Scholar 

  23. Nam CW, Park NH, Park BR, Shin JW, Jung SW, Na YW, et al. Mitotic checkpoint gene MAD1 in hepatocellular carcinoma is associated with tumor recurrence after surgical resection. J Surg Oncol. 2008;97:567–71.

    Article  PubMed  Google Scholar 

  24. Zou L, Zhang P, Luo C, Tu Z. Mad1 suppresses bladder cancer cell proliferation by inhibiting human telomerase reverse transcriptase transcription and telomerase activity. Urology. 2006;67:1335–40.

    Article  PubMed  Google Scholar 

  25. Osaki M, Inoue T, Yamaguchi S, Inaba A, Tokuyasu N, Jeang KT, et al. MAD1 (mitotic arrest deficiency 1) is a candidate for a tumor suppressor gene in human stomach. Virchows Arch. 2007;451:771–9.

    Article  CAS  PubMed  Google Scholar 

  26. Bhattacharjya S, Nath S, Ghose J, Maiti GP, Biswas N, Bandyopadhyay S, et al. miR-125b promotes cell death by targeting spindle assembly checkpoint gene MAD1 and modulating mitotic progression. Cell Death Differ. 2013;20:430–42.

    Article  CAS  PubMed  Google Scholar 

  27. Rottmann S, Menkel AR, Bouchard C, Mertsching J, Loidl P, Kremmer E, et al. Mad1 function in cell proliferation and transcriptional repression is antagonized by cyclin E/CDK2. J Biol Chem. 2005;280:15489–92.

    Article  CAS  PubMed  Google Scholar 

  28. Chen Y, Yeh PC, Huang JC, Yeh CC, Juang YL. The spindle checkpoint protein MAD1 regulates the expression of E-cadherin and prevents cell migration. Oncol Rep. 2012;27:487–91.

    CAS  PubMed  Google Scholar 

  29. Rottmann S, Lüscher B. The Mad side of the Max network: antagonizing the function of Myc and more. Curr Top Microbiol Immunol. 2006;302:63–122.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work is supported by a grant from the National Natural Science Foundation of China (No.30772540 and No.81172214).

Author information

Authors and Affiliations

  1. Department of Pediatrics, The Affiliated Tumor Hospital, Harbin Medical University, Haping Road 150, Nangang District, Harbin, 150081, China

    Dandan Li & Meiyan Liu

  2. The Fourth Department of Medical Oncology, The Affiliated Tumor Hospital, Harbin Medical University, Haping Road 150, Nangang District, Harbin, 150081, China

    Qingwei Meng, Huijuan Zhang, Ting Feng & Li Cai

Authors
  1. Dandan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qingwei Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huijuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ting Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meiyan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Cai.

Ethics declarations

Compliance with ethical standards

This study was approved by the Medical Ethics Committee of Harbin Medical University, and informed consent was obtained from the participating patients.

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, D., Meng, Q., Zhang, H. et al. Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection. Tumor Biol. 37, 4393–4398 (2016). https://doi.org/10.1007/s13277-015-4302-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4302-5

Keywords

Search

Navigation